Jeffrey Gregg, M.D.

University of California, Davis
email: jpgregg@ucdavis.edu

Grants

Targeted Chemoprevention in a Mouse Model for DCIS 2005 (Cycle 11)
IDEA (Innovative, Developmental, and Exploratory Awards) 11IB-0123 $135,326
Analysis of Genes Predictive of Breast Cancer Metastasis 2000 (Cycle VI)
New Investigator 6KB-0074 $221,925


Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
  Periodical: Clinical Cancer Research
  Author(s): Namba R, et al, and Gregg JP
  Yr: 2006 Vol: 12 Nbr: 8 Pgs: 2613-2621
  Associated Grant: Targeted Chemoprevention in a Mouse Model for DCIS
 
Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography.
  Periodical: Journal of Mammary Gland Biology and Neoplasia
  Author(s): Abbey CK, Borowsky AD, Gregg JP, Cardiff RD, Cherry SR
  Yr: 2006 Vol: 11 Nbr: 2 Pgs: 137-49
  Associated Grant: Targeted Chemoprevention in a Mouse Model for DCIS
 
Heterogeneity of mammary lesions represent molecular differences.
  Periodical: BMC Cancer
  Author(s): Namba R, et al., and Gregg JP
  Yr: 2006 Vol: 6 Nbr: Pgs: 275
  Associated Grant: Targeted Chemoprevention in a Mouse Model for DCIS
 
Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ
  Periodical: Breast Cancer Research
  Author(s): Ruria Namba, Lawrence JT Young, Jeannie E Maglione, Erik T McGoldrick, Stephenie Liu,
  Yr: 2005 Vol: 7 Nbr: 6 Pgs: 881-889
  Associated Grant: Targeted Chemoprevention in a Mouse Model for DCIS